A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B
Status:
Recruiting
Trial end date:
2022-07-25
Target enrollment:
Participant gender:
Summary
The aim of the prospective real-world study is to evaluate whether sequential combination
therapy with pegylated interferon plus entecavir/tenofovir could induce higher rates of HBsAg
loss in nucleoside-treated patients with chronic hepatitis B compared to continuous
nucleoside treatment.